Every 10-Q that PLUS THERAPEUTICS, Inc. (PSTV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow PSTV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PSTV filings page.
Cerenome, Inc. reported for the quarter and six months ended June 30, 2026 that it remains a development-stage CNS oncology company with no product sales and relies primarily on grant funding and capital markets. Grant revenue was $0.4 million for the quarter and $1.4 million year‑to‑date, down from 2025, while total operating expenses rose sharply to $9.5 million for the quarter and $17.6 million for the first half of 2026, producing a six‑month net loss of $15.9 million.
Total assets were $14.0 million, including $2.4 million in cash and cash equivalents and $6.2 million in investments, against total liabilities of $8.6 million. Net cash used in operating activities was $13.4 million in the first half, partially offset by $10.1 million of net cash provided by financing, including a January 2026 underwritten equity offering and at‑the‑market sales. Management states that recurring losses, high cash burn, and dependence on external financing raise substantial doubt about the Company’s ability to continue as a going concern. The company executed a 1‑for‑25 reverse stock split and is currently in compliance with Nasdaq stockholders’ equity and minimum bid price requirements, with monitoring continuing through August 22, 2026.
Plus Therapeutics, Inc. reported a net loss of $6.9 million for the three months ended March 31, 2026, on grant revenue of $1.0 million, reflecting heavy research and administrative spending as it develops CNS cancer diagnostics and radiopharmaceuticals.
Cash and cash equivalents were $3.0 million with net cash used in operations of $6.2 million, and management states there is substantial doubt about the company’s ability to continue as a going concern without additional financing. Stockholders’ equity increased to $12.0 million, supported by a January 2026 public offering and a 1‑for‑25 reverse stock split that helped the company regain compliance with Nasdaq’s minimum bid requirement.
Plus Therapeutics (PSTV) filed its Q3 2025 10‑Q showing wider year‑to‑date losses but a stronger balance sheet from recent financings. The company reported a Q3 net loss of $4.4M on grant revenue of $1.4M. Operating expenses were driven by research and development of $2.4M and general and administrative of $3.4M.
Liquidity improved: cash and cash equivalents were $13.3M and total assets $18.7M at September 30, 2025. Stockholders’ equity turned positive to $5.1M from a deficit at year‑end, aided by capital raises, including sales under a Lincoln Park Purchase Agreement. Year‑to‑date financing cash inflows were $27.5M. The company recognized $3.8M in CPRIT grant revenue year‑to‑date; the $3.0M Department of Defense award remains deferred.
The filing states substantial doubt about continuing as a going concern due to ongoing losses and funding needs. Nasdaq confirmed compliance with equity standards, but PSTV remains out of compliance with the $1.00 minimum bid price requirement, with a grace period through November 12, 2025. Shares outstanding were 137,429,055 as of October 29, 2025.